Nagasaka, Misako
Zhang, Shannon S.
Baca, Yasmine
Xiu, Joanne
Nieva, Jorge
Vanderwalde, Ari
Swensen, Jeffrey J.
Spetzler, David
Korn, Wolfgang Michael
Raez, Luis E.
Liu, Stephen V.
Ou, Sai-Hong Ignatius
Article History
Received: 27 March 2023
Accepted: 28 September 2023
First Online: 18 October 2023
Declarations
:
: This study was conducted in accordance with guidelines of the Declaration of Helsinki, Belmont report, and U.S. Common rule. In keeping with 45 CFR 46.101(b)(4), this study was performed utilizing retrospective, deidentified clinical data. Therefore this study is considered IRB exempt and no patient consent was necessary from the subject. The need for written informed consent and ethical approval was waived by the University of California Irvine ethic committee due to the retrospective nature of the study.
: Not applicable as no individual identifying image or information are included in the manuscript.
: There was no funding allocated for this research and there are no direct conflicts of interest. Potential COI from all authors are listed below.Conflict of interest statementMN is on the advisory board for AstraZeneca, Daiichi Sankyo, Takeda, Novartis, EMD Serono, Janssen, Pfizer, Eli Lilly and Company and Genentech; consultant for Caris Life Sciences (virtual tumor board); speaker for Blueprint Medicines and Takeda; and reports travel support from AnHeart Therapeutics.SSZ has no disclosures.YB, JX, JS, DS are employees and shareholders of Caris Life Sciences.JN discloses the following: Consulting: Aadi Biosciences, Astra Zeneca, Bristol Myers Squibb, Fujirebio, G1 Therapeutics, Genentech, Mindmed, Naveris, Takeda, Western Oncolytics., Research Support: Genentech, Merck, Intellectual Property: Cansera and Ownership Interests: Cansera, Epic Sciences, Indee Bio, Quantgene.AV is an employee of Caris Life Sciences and a consultant for West Cancer Center and George Clinical.WMK has stock ownership of Caris Life Sciences.LER has received research support from BMS, Astra-Zeneca, Roche, Pfizer, Merck, Velos, Guardant Health, Natera, Genentech, Bio Alta.SVL has received advisory fees from AstraZeneca, Blueprint, Bristol-Myers Squibb, Celgene, G1 Therapeutics, Genentech/Roche, Guardant Health, Inivata, Janssen, Jazz, Lilly, Merck/MSD, PharmaMar, Pfizer, Regeneron and Takeda; non-financial support from AstraZeneca, Boehringer-Ingelheim, Genentech/Roche, and Merck/MSD; and research grant support (to institution) from Alkermes, AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Corvus, Genentech, Janssen, Lilly, Lycera, Merck, Molecular Partners, Pfizer, Rain Therapeutics, RAPT, Spectrum, and Turning Point Therapeutics.SHIO has stock ownership and was on the scientific advisory board of Turning Point Therapeutics Inc (until Feb 28, 2019), is a member of the SAB of Elevation Oncology, and has received speaker honorarium from Merck, Roche/Genentech, Astra Zeneca, Takeda/ARIAD and Pfizer; has received advisory fees from Roche/Genentech, Astra Zeneca, Takeda/ARIAD, Pfizer, Foundation Medicine Inc, Spectrum, Daiichi Sankyo, Jassen/JNJ, and X-Covery.